Guardant Health

We’re grateful to team up with Patrick Dempsey this National Colorectal Cancer (CRC) Awareness Month to show America that you can now screen for colon and rectal cancers with just a blood test — from a trusted leader in blood tests for cancer for more than a decade. After witnessing his mother’s journey with cancer, Patrick has become a powerful voice for expanding access to lifesaving cancer screening and care. He’s passionate about raising awareness this #ColorectalCancerAwarenessMonth, because when you catch CRC in its early stages, it’s more treatable. Learn why Patrick was screened for CRC with the Shield™ blood test at shieldcancerscreen.com. For Important Product Information, including precaution and limitations, visit shieldcancerscreen.info/Precaution. Shield is available by prescription only and is FDA approved. Intended for US audiences only. Patrick Dempsey is a paid partner of Guardant Health. #ColorectalCancer #Cancer #CancerAwareness

Shield Across America makes a Vegas pit stop at the Pennzoil 400 🏁 #CRCAwarenessIntoAction news3lv.com/news/local/pen…

@kemu808 We appreciate the positive feedback!

.@GuardantHealth Shield ad is 🔥‼️ Well done!

New findings from a national survey conducted by The @HarrisPoll give insight into the barriers driving today's screening gap — and the growing demand for easier options like Shield™, the first and only FDA-approved blood test for primary #ColorectalCancer screening. Explore what screening-eligible Americans are saying: bit.ly/4bb6siw #CRCAwarenessIntoAction

“What's nice about Shield by Guardant is that it’s just a blood test that eliminates a lot of the obstacles and makes it easier to screen." Inspiring to see Patrick share the importance of #ColorectalCancer screening in a new interview with @MensHealthMag, including his experience getting screened with Shield™.

Action shot! 📸 A huge thank you to the 500+ volunteers who joined us on March 1 to bring our United in Blue installation to life. Together, we placed 27,000+ blue flags to represent the young lives impacted by #colorectalcancer in 2030. A huge thank you to our wonderful sponsors for helping make this installation possible: @Merck, @Amgen, @JNJNews, @Olympus_Corp, @genentech, @ExactSciences, @GuardantHealth, @SMMT_TX, @NateraGenetics, @pfizer, @GSK, @DUDEwipes , @GeneoscopyCo, @ExelixisInc, & @DaiichiSankyoUS

Access, activated. Our collaboration with @QuestDX is now live — making Shield™ accessible through Quest’s national test ordering and collection network. Physicians nationwide can now access Shield directly through their existing Quest account and EHR systems, integrating blood-based #ColorectalCancer screening into routine care across one of the largest diagnostic ecosystems in the U.S. #Innovation matters most when it reaches patients. Today, that reach expands nationwide. Details: bit.ly/3PaJdMU

#CancerCare is shifting from reaction to earlier, data-driven action. On the Heart of Healthcare Podcast, our co-CEO Helmy Eltoukhy discusses pioneering the #LiquidBiopsy industry and the journey to co-founding Guardant Health with AmirAli Talasaz, and what it takes to turn breakthrough biochemistry, data, and AI into tools that work in everyday clinical practice. Building in diagnostics means aligning innovation with evidence, reimbursement, and real-world delivery — to deliver breakthrough technology to patients at scale. 🎧 Listen in: bit.ly/4b0zW2D

Today, March 6th, is Dress In Blue Day. We're asking you to wear blue because we've had Enough. 🙅‍♂️ Enough of colorectal cancer being the top cause of cancer deaths in people under 50. 🙅‍♂️ Enough of colorectal cancer being underfunded. 🙅‍♂️ Enough delay. Join us this #DressInBlueDay to honor those impacted by colorectal cancer. Let's tell the world we’ve had #EnoughCRC. Learn more: bit.ly/26March-DIBD

A new route for #ColorectalCancer screening. Today we launched Shield Across America — a coast-to-coast mobile tour bringing Shield™, the first and only FDA-approved blood test for primary colorectal cancer screening, to more than 100 communities nationwide. During #ColorectalCancerAwarenessMonth, we’re focused on communities facing the largest screening disparities — especially rural areas with the greatest barriers to screening and the highest colorectal cancer incidence and mortality rates — bringing guideline-recommended screening directly into neighborhoods across the country. Details: bit.ly/4aUgumE #CRCAwarenessIntoAction

We welcome the @WhiteHouse’s call to prioritize #ColorectalCancer screening this #ColorectalCancerAwarenessMonth. CRC is the leading cause of cancer death in adults under 50—yet it is highly treatable when detected early. Shield™ by Guardant Health, our FDA-approved blood test, offers an accessible and convenient way to get screened starting at age 45. whitehouse.gov/briefings-stat…

Patrick Dempsey’s interest in spreading awareness for colorectal cancer — the leading cause of cancer-related deaths in adults under 50 — stems from his mom’s battle with ovarian cancer. Dempsey, who is partnering with Guardant Health to encourage early colorectal cancer screening, shares how the Dempsey Center helps patients and their families.

March marks the start of #ColorectalCancerAwarenessMonth. Awareness matters, but action can make a life-saving difference. By prioritizing #EarlyDetection, expanding access to #Screening, and helping more patients get up to date on CRC screening, we can change what’s possible for patients facing #ColorectalCancer. Join us throughout March as we turn #CRCAwarenessIntoAction.

Kicking off our 54-mile ride with @GuardantHealth 🚲🙌

Today, our co-CEO Helmy Eltoukhy joins #LNIF26 for CODE BLUE: When Tech Rewrites Medicine — a conversation on how AI, quantum computing, and precision medicine are reshaping healthcare at scale. The future of oncology will be built at the intersection of breakthrough science and bold technology — and that future is taking shape now. #LakeNonaImpactForum #FutureOfHealth

Back in the saddle for DCC XVI! We’re honored to once again sponsor the 54-mile ride at the Dolphins Cancer Challenge in support of the cancer community. Stop by our booth to learn how blood-based tests like Guardant Reveal® can provide clearer, earlier answers about cancer.

At the @UN's 11th International Day of Women & Girls in Science Assembly, our co-CEO Helmy Eltoukhy shared a clear message: the future of healthcare depends on shifting from reacting to symptoms to acting on signals. It’s a move from sick care to true healthcare — powered by data, AI, and actionable insights at population scale. Watch the session: webtv.un.org/en/asset/k1l/k…

What will it take to accelerate the future of oncology? Tomorrow at Cancer 2035: A Roadmap for the Future, hosted by the @MilkenInstitute, our co-CEO Helmy Eltoukhy joins fellow leaders for the panel Accelerating the Future of Oncology. AI, genomics, and data science are redefining how cancer is discovered and treated. The focus is on pairing these advances with smarter drug development and digital infrastructure to accelerate breakthroughs and deliver measurable impact for patients at scale. Watch live: youtube.com/watch?v=DKd8YP…